Clinical Trials Logo
  1. Home
  2. Other
  3. NCT00262041

Study of the Safety and Immune Response of a Meningococcal Conjugate Vaccine Administered to Healthy Adolescents

Prevention of Meningococcal Disease Clinical Trial

Official title:
A Phase 2, Randomized, Single-blind, Controlled, Multicenter Study to Compare the Safety and Immune Response of One Dose of Novartis Meningococcal ACWY Conjugate Vaccine With the Safety and Immune Response of One Dose of Licensed Meningococcal ACWY Polysaccharide Vaccine Administered to Healthy Adolescents 11 to 17 Years of Age

Clinical Trial Summary

The purpose of this study is to evaluate the safety and immunogenicity of Novartis Meningococcal ACWY Conjugate Vaccine in comparison to licensed meningococcal polysaccharide vaccine administered to healthy adolescents ages 11 to 17 years.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00262041
Study type Interventional
Source Novartis
Contact
Status Completed
Phase Phase 2
Start date October 2004
Completion date March 2006
View Details
See also
  Status Clinical Trial Phase
Completed NCT00262002 - Study of the Safety and Immune Response of a Meningococcal Vaccine Administered to Healthy Infants Phase 2
Completed NCT00262028 - Study of the Safety and Immune Response of a Meningococcal Vaccine Administered to Healthy Children Phase 2